Charlie N. Fong
Private Equity Investor at BDC Venture Capital
Profile
Dr. Charlie N.
Fong joined BDC Venture Capital in 1998.
His experience in the pharmaceutical industry encompasses drug discovery, clinical development, marketing, sales training, medical education, business development, strategic partnerships, intellectual property protection, and bioinformatics.
He has held management positions with P&L, for a division of 70 people.
Prior to joining the BDC, Dr. Fong had 10 years of industrial experience with a multinational pharmaceutical company as well as start ups.
Dr. Fong has post-doctoral training from the University of California, Berkeley.
Charlie N. Fong active positions
| Companies | Position | Start |
|---|---|---|
BDC Venture Capital
 BDC Venture Capital Investment ManagersFinance BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada. | Private Equity Investor | 31/12/1997 |
Former positions of Charlie N. Fong
| Companies | Position | End |
|---|---|---|
Topigen Pharmaceuticals, Inc.
 Topigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topigen Pharmaceuticals, Inc. develops drugs for respiratory diseases. The firm focuses on discovery and development of multiple pathway therapies for respiratory diseases with primary emphasis on asthma, chronic obstructive pulmonary disease, and allergic rhinitis. The company was founded by Paolo Renzi in 2000 and is headquartered in Montréal, Canada. | Director/Board Member | - |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Director/Board Member | - |
Training of Charlie N. Fong
| University of Ottawa | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
BDC Venture Capital
BDC Venture Capital Investment ManagersFinance BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada. | Finance |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Health Technology |
Topigen Pharmaceuticals, Inc.
Topigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topigen Pharmaceuticals, Inc. develops drugs for respiratory diseases. The firm focuses on discovery and development of multiple pathway therapies for respiratory diseases with primary emphasis on asthma, chronic obstructive pulmonary disease, and allergic rhinitis. The company was founded by Paolo Renzi in 2000 and is headquartered in Montréal, Canada. | Health Technology |
- Stock Market
- Insiders
- Charlie N. Fong